Key result
Non-HDL-C matches LDL-C for predicting and reclassifying 20-year cardiovascular disease risk.
Why the study?
Which blood lipid profile biomarkers best predict the 20-year incidence of cardiovascular disease in a primary prevention population?
Cohort (n=1,988)
No
Which blood lipid profile biomarkers best predict the 20-year incidence of cardiovascular disease in a primary prevention population?
Answers are grounded in this paper and cite their sources.
Non-HDL-C has a similar ability to LDL-C in predicting and reclassifying 20-year cardiovascular disease incidence in a middle-aged, apparently healthy population.
Background: The association of blood lipids and apolipoproteins with cardiovascular disease (CVD) is well established. However, there are ongoing discussions on which lipid biomarker could better predict CVD risk in the long term. Aim: To investigate the association of blood lipid profile biomarkers with 20-year incidence of CVD. Materials and Methods: The ATTICA study is a population-based cohort study investigating CVD incidence and relevant risk factors, including lipids, in 3042 primary prevention population of the metropolitan region of Athens. In 2022, the 20-year follow-up was performed in 2169 individuals who agreed to participate. Analyses were adjusted for gender, age, body mass index, smoking, physical activity, adherence to Mediterranean diet, family CVD history, hypertension, diabetes, and lipid-lowering medication at baseline. Results: In total, information from 1988 individuals was analyzed in 20-year follow-up (50% men, 37% family CVD history, 31% hypertension, 7% diabetes, 55% current/past smoking, 18% obesity, 43% hypercholesterolemia, and 12% on lipid-lowering drugs at baseline). During the follow-up, 718 (36.1%) individuals experienced a first CVD event. Total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-high-density-lipoprotein cholesterol (non-HDL-C), and apolipoprotein B were independent predictors of CVD. Among lipid indices, non-HDL-C and LDL-C demonstrated the best correct reclassification ability (continuous Net Reclassification Improvement = 38.4% and 38.0%, respectively). Conclusions: Non-HDL-C has a similar ability with LDL-C to predict and reclassify 20-year CVD incidence in a middle-aged, apparently healthy population.
No takes yet. Share an insight, caveat, or question.
Lagou et al. (2025) conducted a cohort in Cardiovascular disease (n=1,988). Blood lipid profile biomarkers (non-HDL-C and LDL-C) was evaluated on 20-year incidence of CVD (continuous Net Reclassification Improvement = 38.4% and 38.0%). Non-HDL-C and LDL-C demonstrated similar ability to predict and reclassify 20-year cardiovascular disease incidence, with continuous Net Reclassification Improvements of 38.4% and 38.0%.
Synapse has enriched 10 related papers. Consider them for comparative context: